ONN^® - OncLive News Network^®

Best practices when prescribing and managing antibody-drug conjugate therapy as treatment for relapsed/refractory diffuse large B-cell lymphoma.

Nicholas McAndrew, MD, MSCE provides his perspective on how findings reported at ASCO 2021 will impact treatment of patients with PIK3CA-mutated HR+, HER2- advanced breast cancer. In this series, Dr. McAndrew reviews the overall survival results from MONALEESA-3, the joint analysis of SOLAR-1 and X2101, the design and outcomes of the BYLieve trial, and real-world clinical outcomes using alpelisib in patients with PIK3CA-mutated HR+, HER2- advanced breast cancer.

Key opinion leaders in hematology oncology, Eunice Wang, MD and Bijal Shah, MD, MS, review the results of the ZUMA trial of CAR T cell therapy in adult patients with relapsed/refractory ALL. 

Priyanka Sharma, MD, and Lajos Pusztai, MD, PhD, discuss the practice-changing results and real-world implications of the RxPONDER trial for patients with HR+ HER2- breast cancer.

Ralph Boccia, MD and Jim Schwartz, RPh provide key insights into the recent FDA approval of trilaciclib and discuss its impact on the treatment landscape for extensive-stage small cell lung cancer.

Amit Patel, BSc, MBBS, PhD, reviews key takeaways from the 2021 European Society for Blood and Marrow Transplantation symposium regarding the use of CAR T-cell therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.

OncLive will be LIVE with OncLive News Network: On Location at the virtual 2020 San Antonio Breast Cancer Symposium. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented in breast cancer during the virtual conference.

OncLive will be LIVE with OncLive News Network: On Location at the virtual 2020 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented during the virtual conference.